Loading company
$12.87+1.0%Nov 13 close
Next earnings: November 17, 2026
Figures through June 30, 2026, from the 10-Q filed August 11, 2026
Past performance
- 1W
- +3.4%
- 1M
- +5.4%
- 3M
- -31.4%
$12.87+1.0%Nov 13 close
Next earnings: November 17, 2026
Figures through June 30, 2026, from the 10-Q filed August 11, 2026
Eloxx Pharmaceuticals, Inc. is scheduled to report next on November 17, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2012, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2012 | 3 months toDec 31, 2011 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $200K | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Eloxx Pharmaceuticals, Inc. has no earnings call transcript available.
“The second quarter was transformational for Eloxx. Our public offering, with gross proceeds of $66.0 million, together with our uplisting to the Nasdaq Capital Market, has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx’s lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Eloxx Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.